Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , June 01, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of John J.
View HTML
Toggle Summary Novelion Therapeutics Reports First Quarter 2017 Financial Results
Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer   Defined Clinical Development Plan for Zuretinol Following Positive FDA Meeting Company Reiterates FY 2017 Total Net Revenues Guidance Between $155 and $165 million Conference call to be held today at 8:30 a.m.
View HTML
Toggle Summary Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , May 05, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data by
View HTML
Toggle Summary Novelion Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
Conference call and Webcast Scheduled for 8:30am ET
View HTML
Toggle Summary Novelion Therapeutics Announces Presentation at the Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia , April 25, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Bloom
View HTML
Toggle Summary Novelion Therapeutics' Request to Voluntarily Delist from the Toronto Stock Exchange Granted
VANCOUVER, British Columbia , April 19, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that, as part of its cost rationalization
View HTML
Toggle Summary Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society
Open-label study in patients with partial lipodystrophy-associated NASH featured in oral presentation
View HTML
Toggle Summary Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors
VANCOUVER, British Columbia , March 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan , M.D.
View HTML
Toggle Summary Novelion Therapeutics Observes World Lipodystrophy Day
VANCOUVER, British Columbia , March 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced its observance of World Lipodystrophy Day.
View HTML
Toggle Summary Novelion Therapeutics' Subsidiary Announces New Data to be Presented at the Annual Meeting of the Endocrine Society
VANCOUVER, British Columbia and CAMBRIDGE, Mass. , March 30, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, and its subsidiary today announced the
View HTML